Drugs / CMAB807
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06361355 | Nov 2023 → Jun 2024 | — | Taizhou Mabtech Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03925051 | Jul 2019 → Mar 2020 | postmenopausal osteoporosis | Shanghai Biomabs Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04591275 | Mar 2021 → Nov 2024 | postmenopausal osteoporosis | Shanghai Biomabs Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMAB807 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06361355 ↗ |
| Modality | Monoclonal antibody | “CMAB807 is a human monoclonal antibody targeting the key bone resorption mediator RANKL.” NCT03925051 ↗ |
| Route | Subcutaneous | “Subjects will receive a single 60mg of CMAB807 or Prolia® through subcutaneous injection.” NCT03925051 ↗ |